

Dominik Sturm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7300373/publications.pdf>

Version: 2024-02-01

94
papers

19,378
citations

46918

47
h-index

49773

87
g-index

99
all docs

99
docs citations

99
times ranked

19194
citing authors

#	ARTICLE	IF	CITATIONS
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	13.7	2,129
2	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
3	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	7.7	1,551
4	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	13.7	1,068
5	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathologica, 2012, 124, 439-447.	3.9	799
6	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	13.7	765
7	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
8	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	9.4	674
9	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	7.7	633
10	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627
11	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncology, The, 2017, 18, 682-694.	5.1	586
12	Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	13.7	520
13	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nature Reviews Cancer, 2014, 14, 92-107.	12.8	469
14	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	7.7	438
15	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature Medicine, 2013, 19, 901-908.	15.2	388
16	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	0.8	381
17	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	9.4	381
18	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	3.9	277

#	ARTICLE	IF	CITATIONS
19	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	5.1	268
20	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013, 126, 907-915.	3.9	254
21	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. <i>Acta Neuropathologica</i> , 2013, 125, 659-669.	3.9	250
22	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	0.8	250
23	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
24	Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. <i>Journal of Clinical Oncology</i> , 2017, 35, 2370-2377.	0.8	223
25	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	3.9	203
26	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. <i>Acta Neuropathologica</i> , 2014, 128, 279-289.	3.9	191
27	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. <i>Neuro-Oncology</i> , 2018, 20, 123-131.	0.6	184
28	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. <i>Nature Medicine</i> , 2016, 22, 1314-1320.	15.2	183
29	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571.	3.9	176
30	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. <i>Acta Neuropathologica</i> , 2016, 131, 137-146.	3.9	162
31	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157
32	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516.	3.9	144
33	<i>FSTL5</i> Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3852-3861.	0.8	143
34	Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification. <i>Journal of Clinical Oncology</i> , 2010, 28, 3054-3060.	0.8	136
35	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337.	3.9	104
36	Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. <i>European Journal of Cancer</i> , 2017, 73, 38-47.	1.3	101

#	ARTICLE	IF	CITATIONS
37	<i>TP53</i> Mutation Is Frequently Associated With <i>CTNNB1</i> Mutation or <i>MYCN</i> Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 5188-5196.	0.8	100
38	Germline <i>Elongator</i> mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	13.7	94
39	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. <i>Cell</i> , 2020, 183, 1617-1633.e22.	13.5	93
40	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. <i>Cancer Cell</i> , 2015, 28, 715-729.	7.7	90
41	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. <i>Brain Pathology</i> , 2018, 28, 656-662.	2.1	89
42	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . <i>Neuro-Oncology</i> , 2021, 23, 34-43.	0.6	75
43	Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant Histone 3 Tail. <i>Brain Pathology</i> , 2013, 23, 210-216.	2.1	74
44	Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathologica</i> , 2016, 132, 635-637.	3.9	73
45	Integrated molecular characterization of IDH-mutant glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 108-118.	1.8	68
46	Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles. <i>Brain Pathology</i> , 2015, 25, 202-208.	2.1	66
47	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	7.7	65
48	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100.	3.9	52
49	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. <i>Clinical Sarcoma Research</i> , 2017, 7, 9.	2.3	51
50	Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 422-430.	1.8	51
51	Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics. <i>Neuroscience</i> , 2014, 264, 171-185.	1.1	45
52	No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. <i>Klinische Padiatrie</i> , 2016, 228, 113-117.	0.2	44
53	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 255-266.	1.4	42
54	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. <i>Acta Neuropathologica</i> , 2019, 138, 827-835.	3.9	42

#	ARTICLE	IF	CITATIONS
55	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. <i>Cancer Discovery</i> , 2021, 11, 2230-2247.	7.7	39
56	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. <i>Neuropathology</i> , 2015, 35, 538-544.	0.7	38
57	High-grade glioma in very young children: a rare and particular patient population. <i>Oncotarget</i> , 2017, 8, 64564-64578.	0.8	38
58	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. <i>Acta Neuropathologica</i> , 2021, 142, 841-857.	3.9	36
59	The β -catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner. <i>Oncotarget</i> , 2017, 8, 27300-27313.	0.8	35
60	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	3.9	33
61	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104.	1.2	29
62	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017, 134, 155-158.	3.9	26
63	Radiation-induced gliomas represent H3-IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. <i>Nature Communications</i> , 2021, 12, 5530.	5.8	24
64	Oncolytic effects of parvovirus H α 1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. <i>International Journal of Cancer</i> , 2014, 134, 703-716.	2.3	22
65	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	0.6	22
66	A simplified approach using Taqman low-density array for medulloblastoma subgrouping. <i>Acta Neuropathologica Communications</i> , 2019, 7, 33.	2.4	18
67	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069.	3.9	16
68	Gliomas in Children. <i>Seminars in Neurology</i> , 2018, 38, 121-130.	0.5	15
69	Primary central nervous system sarcoma with <i>DICER1</i> mutation—treatment results of a novel molecular entity in pediatric Peruvian patients. <i>Cancer</i> , 2022, 128, 697-707.	2.0	14
70	Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 558-568.	1.5	13
71	Somatostatin receptor subtype 2 (<i>sst2</i>) is a potential prognostic marker and a therapeutic target in medulloblastoma. <i>Child's Nervous System</i> , 2013, 29, 1253-1262.	0.6	12
72	Accurate calling of <i>KIAA1549-BRAF</i> fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 406-414.	1.8	12

#	ARTICLE	IF	CITATIONS
73	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5.	2.4	12
74	Occurrence of high-grade glioma in Noonan syndrome: Report of two cases. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27625.	0.8	11
75	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. <i>American Journal of Neuroradiology</i> , 2019, 40, 1811-1817.	1.2	9
76	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making – A Selected Case Series. <i>Klinische Padiatrie</i> , 2018, 230, 305-313.	0.2	8
77	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. <i>Acta Neuropathologica</i> , 2019, 137, 847-850.	3.9	7
78	Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas. <i>International Journal of Cancer</i> , 2022, 151, 1431-1446.	2.3	6
79	A Systematic Review and Meta-Analysis of Malignant Rhabdoid and Small Cell Undifferentiated Liver Tumors: A Rational for a Uniform Classification. <i>Cancers</i> , 2022, 14, 272.	1.7	5
80	DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. <i>Acta Neuropathologica</i> , 2022, 144, 129-142.	3.9	5
81	Ectopic intracranial retinoblastoma in a 3.5-month-old infant without eye involvement and without evidence of heritability. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27599.	0.8	3
82	Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort. <i>Frontiers in Oncology</i> , 2021, 11, 756025.	1.3	3
83	Reply to J.C. Lindsey et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e348-e349.	0.8	2
84	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. <i>Neuro-Oncology</i> , 2019, 21, ii82-ii82.	0.6	2
85	Revealing the role of SGK1 in the dynamics of medulloblastoma using a mathematical model. <i>Journal of Theoretical Biology</i> , 2014, 354, 105-112.	0.8	1
86	Spontaneous regression of a congenital high-grade glioma – a case report. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab120.	0.4	1
87	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i107-i107.	0.6	1
88	HGG-56. EXTENSIVE MOLECULAR HETEROGENEITY WITHIN H3-/IDH-WILDTYPE PEDIATRIC GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii354-iii354.	0.6	0
89	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2020, 22, iii311-iii311.	0.6	0
90	ALK inhibition as a salvage therapy for a relapsed unclassifiable sarcomatous CNS tumor with EML4/ALK fusion in an infant. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29594.	0.8	0

#	ARTICLE	IF	CITATIONS
91	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. <i>Neuro-Oncology</i> , 2022, 24, i154-i154.	0.6	0
92	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Neuro-Oncology</i> , 2022, 24, i61-i62.	0.6	0
93	HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, i76-i76.	0.6	0
94	Clinical characteristics and outcome of a large cohort of patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2052-2052.	0.8	0